Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients.
Mark CattralSean LukeMichael J KnauerAndrea NorgateJeffrey SchiffNorman MuirheadPatrick P LukePublished in: Clinical transplantation (2018)
It is safe to convert between Prograf and Advagraf 1:1, without major impact on pharmacokinetics or pharmacodynamics in SPK recipients.